References
- Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-6). Transfusion 2007;47:1134–42.
- Eder AF, Kennedy JM, Dy BA, et al. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009; 49:1554–63.
- Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007;47:599–607.
- Eder AF, Dy BA, Herron RM, Strupp A, Dodd RY, Benjamin RJ. Effective reduction of TRALI risk with plasma collected predominantly from male donors. Transfusion 2009; 49(Suppl):45A.
- Tonnetti L, Eder AF, Dy BA, et al. Transfusion-transmitted Babesia microti identified through hemovigilance. Transfusion 2009; 49:2557–63.
- Eder AF, Dy BA, Kennedy J, et al. The American Red Cross Donor Hemovigilance Program: complications of blood donation reported in 2006. Transfusion 2008;48:1809–19.
- Benjamin RJ, Dy BA, Kennedy JM, Notari EP, Eder AF. The relative safety of automated two-unit red blood cell procedures and manual whole-blood collection in young donors. Transfusion 2009; 49:1874–83.
- Eder AF, Hillyer CD, Dy BA, Notari EP, Benjamin RJ. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds. JAMA 2008;299:2279–86.
- Eder AF, Dy BA, Ralston J, et al. Effective reduction of donor reactions on high school drives with standard work guidance. Transfusion 2009;49(Suppl):51A.
- Code of Federal Regulations Title 21 CFR 606.170(a) and (b), 2009 Washington, DC. US Government Printing Office.
- FDA/Centers for Biologics Evaluation and Research. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2008. Available at http://www.fda.gov/Biologics BloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm113649.htm. Accessed August 12, 2009.
- Taylor C, Cohen H, Mold D, et al., on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2008 Annual SHOT Report (2009). www.shotuk.org.
- Fang CT, Chambers LA, Kennedy J, et al. Detection of bacterial contamination in apheresis products: American Red Cross experience, 2004. Transfusion 2005;45:1845–52.
- Wagner SJ, Eder AF. A model to predict the improvement of automated blood culture bacterial detection by doubling platelet sample volume. Transfusion 2007;47:430–3.
- Benjamin RJ, Kline L, Dy BA, et al. Bacterial contamination of whole blood-derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion 2008;48:2348–55.
- Stramer SL. Current risks of transfusion-transmitted agents. Arch Pathol Lab Med 2007;131:702–7.
- Code of Federal Regulations 21 CFR 610.46 Human immunodeficiency virus (HIV) “lookback” requirements; 21 CFR 610.47, Hepatitis C virus (HCV) “lookback” requirements; 2009 Washington, DC. US Government Printing Office. Available at http://frwebgate2.access.gpo.gov/cgi-bin/PDFgate.cgi?WAISdocID=s9imto/3/2/0&WAI Saction=retrieve. Accessed August 12, 2009.
- AABB Association Bulletin 09-06. Transfusion-transmitted Babesia. Bethesda, AABB.
- The US Biovigilance Network. Available at http://www. aabb.org/Content/Programs_and_Services/Data_Center/US_Biovigilance_Network. Accessed December 6, 2009.